Neoplasm related pain (acute) (chronic)
Methodology & AI Transparency ⓘ
Neoplasm related pain (acute) (chronic) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Neoplasm related pain (acute) (chronic) is an ICD-10-CM indexed diagnosis (G89.3) within Neuropathy, Fibromyalgia & Chronic Pain.
- 2 Real-world patient consensus: Mapped to Neuropathy, Fibromyalgia & Chronic Pain under ICD-10-CM G89.3 for Neoplasm related pain (acute) (chronic) clinical workups.
- 3 Typical cash cost range: Workup highlights for Neoplasm related pain (acute) (chronic) (G89.3): multimodal non-opioid neuromodulation [Neoplasm related pain (acute) (chronic) G89.3].
- 4 Top reported side effects / signs: Key Chronic Pain & Nerves biomarkers for Neoplasm related pain (acute) (chronic) (G89.3): hs-CRP & ESR in Neoplasm related pain (acute) (chronic) (G89.3: Inflammatory Check) & HbA1c & 2-Hour in Neoplasm related pain (acute) (chronic) (G89.3: Glucose Tolerance) (HbA1c < 5.6% (G89.3)).
Ask our AI Specialists anything about Neoplasm related pain (acute) (chronic)
What Is Neoplasm related pain (acute) (chronic)?
Neoplasm related pain (acute) (chronic) is an ICD-10-CM indexed diagnosis (G89.3) within Neuropathy, Fibromyalgia & Chronic Pain. Clinical evaluation centers on multimodal non-opioid neuromodulation [Neoplasm related pain (acute) (chronic) G89.3] alongside serial hs-CRP & ESR in Neoplasm related pain (acute) (chronic) (G89.3: Inflammatory Check) tracking (hs-CRP < 1.0 mg/L (G89.3)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Neoplasm related pain (acute) (chronic) (G89.3, Chronic Pain & Nerves) reflects ectopic dorsal root in Neoplasm related pain (acute) (chronic) (G89.3: ganglion sodium-channel firing). longitudinal control is benchmarked via hs-CRP & ESR in Neoplasm related pain (acute) (chronic) (G89.3: Inflammatory Check).
Common Symptoms & Clinical Signs
- • Presentation of Neoplasm related pain (acute) (chronic) (G89.3): widespread musculoskeletal tender in Neoplasm related pain (acute) (chronic) (G89.3: points accompanied by)
- • Secondary Neoplasm related pain (acute) (chronic) clinical sign: localized nerve entrapment in Neoplasm related pain (acute) (chronic) (G89.3: numbness or radiating)
- • Symptom flares in Neoplasm related pain (acute) (chronic) correlating with hs-CRP & ESR in Neoplasm related pain (acute) (chronic) (G89.3: Inflammatory Check) deviation outside hs-CRP < 1.0 mg/L (G89.3)
- • Functional chronic pain & nerves impact requiring multimodal non-opioid neuromodulation [Neoplasm related pain (acute) (chronic) G89.3] evaluation (G89.3)
Neoplasm related pain (acute) (chronic) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G89.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neuropathy, Fibromyalgia & Chronic Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: hs-CRP & ESR in Neoplasm related pain (acute) (chronic) (G89.3: Inflammatory Check) | hs-CRP < 1.0 mg/L (G89.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & 2-Hour in Neoplasm related pain (acute) (chronic) (G89.3: Glucose Tolerance) | HbA1c < 5.6% (G89.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12 & in Neoplasm related pain (acute) (chronic) (G89.3: Methylmalonic Acid) | B12 > 500 pg/mL (G89.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Neoplasm related pain (acute) (chronic)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Tagraxofusp Elzonris • RxCUI 2109059 | CD123 Interaction | 83% | $0.5500 | $ 30.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Neoplasm related pain (acute) (chronic))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Modulation of the clonal burden in patients with lower-risk myelodysplastic Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. Leukemia • 2026-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41526614 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term real-world benefits and safety of vutrisiran in hereditary Results from the HELIOS-A RTE demonstrate relative stability with only modest changes in disease activity, sustained serum TTR reductions, and an acceptable safety profile with long-term vutrisiran treatment in patients. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis • 2026-09-15 • Phase III Randomized Trial | N = 76 | 82/100 | PMID 42290201 ↗ |
Neoplasm related pain (acute) (chronic) Patient Community & “People Like Me” Threads
Filter Neoplasm related pain (acute) (chronic) community threads and patient logs by age, biological sex, dosage, and treatment duration.